DK2001900T3 - Hidtil ukendte isolerede og oprensede stammer af chikungunya virus og polynukleotid- og polypeptidsekvenser, diagnostiske og immunogeniske anvendelser deraf - Google Patents
Hidtil ukendte isolerede og oprensede stammer af chikungunya virus og polynukleotid- og polypeptidsekvenser, diagnostiske og immunogeniske anvendelser deraf Download PDFInfo
- Publication number
- DK2001900T3 DK2001900T3 DK07734896.9T DK07734896T DK2001900T3 DK 2001900 T3 DK2001900 T3 DK 2001900T3 DK 07734896 T DK07734896 T DK 07734896T DK 2001900 T3 DK2001900 T3 DK 2001900T3
- Authority
- DK
- Denmark
- Prior art keywords
- virus
- chik
- fragment
- sequence
- polynucleotide
- Prior art date
Links
- 241001502567 Chikungunya virus Species 0.000 title claims description 67
- 102000040430 polynucleotide Human genes 0.000 title claims description 33
- 108091033319 polynucleotide Proteins 0.000 title claims description 33
- 239000002157 polynucleotide Substances 0.000 title claims description 33
- 230000002163 immunogen Effects 0.000 title description 4
- 239000012634 fragment Substances 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- 102000003886 Glycoproteins Human genes 0.000 claims description 39
- 108090000288 Glycoproteins Proteins 0.000 claims description 39
- 229920001184 polypeptide Polymers 0.000 claims description 39
- 239000013598 vector Substances 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 15
- 238000000338 in vitro Methods 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 3
- 201000009182 Chikungunya Diseases 0.000 description 95
- 241000700605 Viruses Species 0.000 description 72
- 239000002773 nucleotide Substances 0.000 description 37
- 125000003729 nucleotide group Chemical group 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 34
- 125000003275 alpha amino acid group Chemical group 0.000 description 33
- 101710172711 Structural protein Proteins 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 31
- 102000004169 proteins and genes Human genes 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 27
- 241000710929 Alphavirus Species 0.000 description 25
- 150000001413 amino acids Chemical group 0.000 description 22
- 102100022681 40S ribosomal protein S27 Human genes 0.000 description 21
- 230000003612 virological effect Effects 0.000 description 18
- 230000035772 mutation Effects 0.000 description 14
- 238000006467 substitution reaction Methods 0.000 description 14
- 108091035707 Consensus sequence Proteins 0.000 description 12
- 241000710961 Semliki Forest virus Species 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 101800000515 Non-structural protein 3 Proteins 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 210000002845 virion Anatomy 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical group 0.000 description 9
- 101000666833 Autographa californica nuclear polyhedrosis virus Uncharacterized 20.8 kDa protein in FGF-VUBI intergenic region Proteins 0.000 description 8
- 101000977023 Azospirillum brasilense Uncharacterized 17.8 kDa protein in nodG 5'region Proteins 0.000 description 8
- 101000977027 Azospirillum brasilense Uncharacterized protein in nodG 5'region Proteins 0.000 description 8
- 101000962005 Bacillus thuringiensis Uncharacterized 23.6 kDa protein Proteins 0.000 description 8
- 101000961984 Bacillus thuringiensis Uncharacterized 30.3 kDa protein Proteins 0.000 description 8
- 101000644901 Drosophila melanogaster Putative 115 kDa protein in type-1 retrotransposable element R1DM Proteins 0.000 description 8
- 101000785191 Drosophila melanogaster Uncharacterized 50 kDa protein in type I retrotransposable element R1DM Proteins 0.000 description 8
- 101000747704 Enterobacteria phage N4 Uncharacterized protein Gp1 Proteins 0.000 description 8
- 101000747702 Enterobacteria phage N4 Uncharacterized protein Gp2 Proteins 0.000 description 8
- 101000861206 Enterococcus faecalis (strain ATCC 700802 / V583) Uncharacterized protein EF_A0048 Proteins 0.000 description 8
- 101000769180 Escherichia coli Uncharacterized 11.1 kDa protein Proteins 0.000 description 8
- 101000758599 Escherichia coli Uncharacterized 14.7 kDa protein Proteins 0.000 description 8
- 101000768930 Lactococcus lactis subsp. cremoris Uncharacterized protein in pepC 5'region Proteins 0.000 description 8
- 101000976301 Leptospira interrogans Uncharacterized 35 kDa protein in sph 3'region Proteins 0.000 description 8
- 101000976302 Leptospira interrogans Uncharacterized protein in sph 3'region Proteins 0.000 description 8
- 101000778886 Leptospira interrogans serogroup Icterohaemorrhagiae serovar Lai (strain 56601) Uncharacterized protein LA_2151 Proteins 0.000 description 8
- 101000658690 Neisseria meningitidis serogroup B Transposase for insertion sequence element IS1106 Proteins 0.000 description 8
- 101000748660 Pseudomonas savastanoi Uncharacterized 21 kDa protein in iaaL 5'region Proteins 0.000 description 8
- 101000584469 Rice tungro bacilliform virus (isolate Philippines) Protein P1 Proteins 0.000 description 8
- 101001121571 Rice tungro bacilliform virus (isolate Philippines) Protein P2 Proteins 0.000 description 8
- 101000818096 Spirochaeta aurantia Uncharacterized 15.5 kDa protein in trpE 3'region Proteins 0.000 description 8
- 101000818098 Spirochaeta aurantia Uncharacterized protein in trpE 3'region Proteins 0.000 description 8
- 101000766081 Streptomyces ambofaciens Uncharacterized HTH-type transcriptional regulator in unstable DNA locus Proteins 0.000 description 8
- 101001026590 Streptomyces cinnamonensis Putative polyketide beta-ketoacyl synthase 2 Proteins 0.000 description 8
- 101000804403 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HIT-like protein Synpcc7942_1390 Proteins 0.000 description 8
- 101000750910 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized HTH-type transcriptional regulator Synpcc7942_2319 Proteins 0.000 description 8
- 101000750896 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Uncharacterized protein Synpcc7942_2318 Proteins 0.000 description 8
- 101000644897 Synechococcus sp. (strain ATCC 27264 / PCC 7002 / PR-6) Uncharacterized protein SYNPCC7002_B0001 Proteins 0.000 description 8
- 101000916321 Xenopus laevis Transposon TX1 uncharacterized 149 kDa protein Proteins 0.000 description 8
- 101000916336 Xenopus laevis Transposon TX1 uncharacterized 82 kDa protein Proteins 0.000 description 8
- 101001000760 Zea mays Putative Pol polyprotein from transposon element Bs1 Proteins 0.000 description 8
- 101000760088 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 20.9 kDa protein Proteins 0.000 description 8
- 101000678262 Zymomonas mobilis subsp. mobilis (strain ATCC 10988 / DSM 424 / LMG 404 / NCIMB 8938 / NRRL B-806 / ZM1) 65 kDa protein Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 230000036961 partial effect Effects 0.000 description 8
- 241000255925 Diptera Species 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010012310 Dengue fever Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108010001267 Protein Subunits Proteins 0.000 description 6
- 102000002067 Protein Subunits Human genes 0.000 description 6
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 208000025729 dengue disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000710944 O'nyong-nyong virus Species 0.000 description 5
- 101800000980 Protease nsP2 Proteins 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 208000001490 Dengue Diseases 0.000 description 4
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 4
- 101710152005 Non-structural polyprotein Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 101710114167 Polyprotein P1234 Proteins 0.000 description 4
- 101710124590 Polyprotein nsP1234 Proteins 0.000 description 4
- 108020005038 Terminator Codon Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000012894 fetal calf serum Substances 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000010166 immunofluorescence Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000013081 phylogenetic analysis Methods 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 208000032274 Encephalopathy Diseases 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 241000710960 Sindbis virus Species 0.000 description 3
- 101710132906 Structural polyprotein Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 206010014599 encephalitis Diseases 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000011475 meningoencephalitis Diseases 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000256173 Aedes albopictus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 208000004293 Chikungunya Fever Diseases 0.000 description 2
- 206010067256 Chikungunya virus infection Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241001281764 Furcifer Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000616172 Homo sapiens Splicing factor 3B subunit 3 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 101710125507 Integrase/recombinase Proteins 0.000 description 2
- 238000010629 Molecular evolutionary genetics analysis Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 2
- 238000012952 Resampling Methods 0.000 description 2
- 201000007009 Ross river fever Diseases 0.000 description 2
- 102100021816 Splicing factor 3B subunit 3 Human genes 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- 108010087302 Viral Structural Proteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000000799 fusogenic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 230000000521 hyperimmunizing effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- 241000256111 Aedes <genus> Species 0.000 description 1
- 241001221827 Aedes luteocephalus Species 0.000 description 1
- 241001302714 Aedes pseudoscutellaris Species 0.000 description 1
- 208000007887 Alphavirus Infections Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 241000256186 Anopheles <genus> Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 241001397104 Dima Species 0.000 description 1
- 244000114635 Dombeya acutangula Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 206010068052 Mosaicism Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241001163844 Olive mild mosaic virus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710132593 Protein E2 Proteins 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010012974 RNA triphosphatase Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101800001473 Spike glycoprotein E2 Proteins 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- -1 but not limited to Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000009133 cooperative interaction Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000012909 foetal bovine serum Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003312 immunocapture Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 230000000174 oncolytic effect Effects 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000020978 protein processing Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000009962 secretion pathway Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000010464 virion assembly Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/181—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE or semliki forest virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Claims (12)
1. Isoleret og oprenset vild stamme 05,115 af chikungunya virus (CHIKV) i stand til at in vitro inficere humane celler og hvor dets genom består af sekvensen vist i 5 figur 4.
2. Isoleret og oprenset polynukleotid bestående af sekvensen som vist i figur 4.
3. Fragment af polynukleotidet ifølge krav 2, hvor det koder for ektodomænet af 10 glycoprotein E2.
4. Fragment af polynukleotidet ifølge krav 2, hvor det koder for en opløselig form af glycoprotein E2.
5. Fragment af polynukleotidet ifølge krav 2, hvor det koder for ektodomænet af glycoprotein El.
6. Vektor omfattende et fragment ifølge et hvilket som helst af kravene 3 til 5. 20 7. Værtscelle omfattende en vektor ifølge krav 6.
8. Oprenset polypeptid kodet for af et polynukleotidfragment ifølge et hvilket som helst af kravene 3 til 5.
9. Oprenset polypeptid bestående af sekvensen ifølge figur 40.
10. Anvendelse af et element valgt fra gruppen bestående af: - en 05,115 chikungunya virus stamme bestående af genomen ifølge figur 4; 30 - et polynukleotid bestående af sekvensen vist i figur 4; - et fragment ifølge et hvilket som helst af kravene 3 til 5; - en vektor ifølge krav 6; - en værtscelle ifølge krav 7; - et polypeptid ifølge et hvilket som helst af kravene 8 eller 9; og - monoklonale eller polyklonale antistoffer, eller fragment deraf, som specifikt binder til et polypeptid ifølge et hvilket som helst af kravene 8 og 9; til in vitro -detekteringen af et CHIKV associeret med en arbovirose.
11. Anvendelse af et element valgt fra gruppen bestående af: - en 05,115 chikungunya virus stamme omfattende en genom ifølge figur 4; - et polynukleotid bestående af sekvensen vist i figur 4; - et fragment ifølge et hvilket som helst af kravene 3 til 5; - en vektor ifølge krav 6; - en værtscelle ifølge krav 7; og - et polypeptid ifølge et hvilket som helst af kravene 8 eller 9; til fremstilingen af en sammensætning som forhindrer og/eller behandler en arbovirose.
12. Sammensætning omfattende mindst et element valgt fra gruppen bestående af: - en 05,115 chikungunya virus stamme omfattende en genom ifølge figur 4; - et polynukleotid bestående af sekvensen vist i figur 4; - et fragment ifølge et hvilket som helst af kravene 3 til 5; - en vektor ifølge krav 6; - en værtscelle ifølge krav 7; og - et polypeptid ifølge et hvilket som helst af kravene 8 eller 9, og endvidere omfattende en acceptabel bærer.
13. Kit til detekteringen af en CHIKV associeret med en arbovirose, omfattende mindst en pakning omfattende mindst et element valgt fra gruppen bestående af: - en 05,115 chikungunya virus stamme bestående af genomen ifølge figur 4; - et polynukleotid bestående af sekvensen vist i figur 4; - et fragment ifølge et hvilket som helst af kravene 3 til 5; - en vektor ifølge krav 6; - en værtscelle ifølge krav 7; - et polypeptid ifølge et hvilket som helst af kravene 8 eller 9; og monoklonale eller polyklonale antistoffer, eller fragment deraf, som specifikt binder til et polypeptid ifølge et hvilket som helst af kravene 8 og 9.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002538898A CA2538898A1 (fr) | 2006-03-15 | 2006-03-15 | Nouvelles souches isolees et purifiees du virus chikungunya et sequences nucleotidiques et peptidiques, applications diagnostiques et immunogeniques |
| CA 2545597 CA2545597A1 (en) | 2006-03-15 | 2006-04-04 | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| PCT/IB2007/001716 WO2007105111A2 (en) | 2006-03-15 | 2007-03-15 | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2001900T3 true DK2001900T3 (da) | 2015-07-27 |
Family
ID=38481184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK07734896.9T DK2001900T3 (da) | 2006-03-15 | 2007-03-15 | Hidtil ukendte isolerede og oprensede stammer af chikungunya virus og polynukleotid- og polypeptidsekvenser, diagnostiske og immunogeniske anvendelser deraf |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20100055105A1 (da) |
| EP (2) | EP2001900B1 (da) |
| JP (2) | JP5923232B2 (da) |
| AU (1) | AU2007226231B2 (da) |
| CA (2) | CA2545597A1 (da) |
| DK (1) | DK2001900T3 (da) |
| ES (1) | ES2543839T3 (da) |
| HU (1) | HUE025076T2 (da) |
| PL (1) | PL2001900T3 (da) |
| PT (1) | PT2001900E (da) |
| SI (1) | SI2001900T1 (da) |
| WO (1) | WO2007105111A2 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2545597A1 (en) * | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| US8865184B2 (en) * | 2006-09-01 | 2014-10-21 | Bharat Biotech International Limited | Vaccine for chikungunya virus infection |
| CA2598966A1 (en) * | 2007-09-07 | 2009-03-07 | Institut Pasteur | Anti-chikungunya monoclonal antibodies and uses thereof |
| FR2921064A1 (fr) * | 2007-09-14 | 2009-03-20 | Biomerieux Sa | Oligonucleotides, utilisation, methode de detection et kit permettant de diagnostiquer la presence du gene e1 du virus du chikungunya |
| AU2009231559B2 (en) * | 2008-04-04 | 2015-10-22 | The Trustees Of The University Of Pennsylvania | Consensus sequences of Chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
| CA3128538C (en) | 2008-04-21 | 2023-08-08 | Gen-Probe Incorporated | Method for detecting chikungunya virus |
| AU2010217230B2 (en) * | 2009-02-25 | 2012-05-10 | Bigtec Private Limited | Probes and primers for detection of Chikungunya |
| CN103476788A (zh) * | 2010-12-10 | 2013-12-25 | 新加坡科技研究局 | 免疫原性屈曲病毒肽 |
| WO2012131580A1 (en) * | 2011-03-28 | 2012-10-04 | Scms, Institute Of Bioscience And Biotechnology Research And Development | Method of detecting chikungunya virus utilizing a recombinant el coat peptide antigen |
| US9701719B2 (en) | 2012-09-27 | 2017-07-11 | Research Development Foundation | Attenuated Chikungunya virus |
| EP2712871A1 (en) | 2012-09-27 | 2014-04-02 | Institut Pasteur | Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications |
| CN103286031B (zh) * | 2013-05-16 | 2015-07-22 | 中国科学院光电研究院 | 一种高频、高速的微米级液滴产生装置 |
| CA3030451C (en) | 2016-07-15 | 2023-09-05 | Etubics Corporation | Compositions and methods for alphavirus vaccination |
| US11286295B2 (en) | 2016-10-20 | 2022-03-29 | Sanofi | Anti-CHIKV monoclonal antibodies directed against the E2 structural protein |
| NZ761619A (en) * | 2017-09-21 | 2024-03-22 | Valneva Se | Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3 |
| US11827675B2 (en) | 2018-09-27 | 2023-11-28 | Texas Tech University System | Stable cell line secreting Chikungunya Virus (CHIKV) virus like particles (VLP) for vaccines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100233209A1 (en) * | 2005-08-11 | 2010-09-16 | Higgs Stephen T | Chikungunya virus infectious clones and uses therefor |
| CA2545597A1 (en) * | 2006-03-15 | 2007-09-15 | Institut Pasteur | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| US8865184B2 (en) * | 2006-09-01 | 2014-10-21 | Bharat Biotech International Limited | Vaccine for chikungunya virus infection |
-
2006
- 2006-04-04 CA CA 2545597 patent/CA2545597A1/en not_active Abandoned
-
2007
- 2007-03-15 JP JP2008558940A patent/JP5923232B2/ja active Active
- 2007-03-15 PL PL07734896T patent/PL2001900T3/pl unknown
- 2007-03-15 PT PT77348969T patent/PT2001900E/pt unknown
- 2007-03-15 DK DK07734896.9T patent/DK2001900T3/da active
- 2007-03-15 HU HUE07734896A patent/HUE025076T2/en unknown
- 2007-03-15 CA CA2646520A patent/CA2646520C/en active Active
- 2007-03-15 ES ES07734896.9T patent/ES2543839T3/es active Active
- 2007-03-15 SI SI200731678T patent/SI2001900T1/sl unknown
- 2007-03-15 AU AU2007226231A patent/AU2007226231B2/en active Active
- 2007-03-15 EP EP07734896.9A patent/EP2001900B1/en active Active
- 2007-03-15 US US12/225,111 patent/US20100055105A1/en not_active Abandoned
- 2007-03-15 EP EP20120153717 patent/EP2460822A3/en not_active Withdrawn
- 2007-03-15 WO PCT/IB2007/001716 patent/WO2007105111A2/en active Application Filing
-
2012
- 2012-12-05 JP JP2012266306A patent/JP6104584B2/ja active Active
-
2014
- 2014-07-18 US US14/335,065 patent/US9442114B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2007226231A1 (en) | 2007-09-20 |
| US20100055105A1 (en) | 2010-03-04 |
| CA2646520A1 (en) | 2007-09-20 |
| SI2001900T1 (sl) | 2015-09-30 |
| US9442114B2 (en) | 2016-09-13 |
| EP2460822A2 (en) | 2012-06-06 |
| WO2007105111A2 (en) | 2007-09-20 |
| CA2646520C (en) | 2018-05-15 |
| ES2543839T3 (es) | 2015-08-24 |
| EP2460822A3 (en) | 2012-09-26 |
| JP2013126414A (ja) | 2013-06-27 |
| PT2001900E (pt) | 2015-09-15 |
| EP2001900A2 (en) | 2008-12-17 |
| US20150111197A1 (en) | 2015-04-23 |
| PL2001900T3 (pl) | 2015-10-30 |
| EP2001900B1 (en) | 2015-04-29 |
| JP2009529868A (ja) | 2009-08-27 |
| AU2007226231B2 (en) | 2013-07-11 |
| JP6104584B2 (ja) | 2017-03-29 |
| CA2545597A1 (en) | 2007-09-15 |
| HUE025076T2 (en) | 2016-02-29 |
| JP5923232B2 (ja) | 2016-05-24 |
| WO2007105111A3 (en) | 2008-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2001900T3 (da) | Hidtil ukendte isolerede og oprensede stammer af chikungunya virus og polynukleotid- og polypeptidsekvenser, diagnostiske og immunogeniske anvendelser deraf | |
| Schuffenecker et al. | Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak | |
| Kofler et al. | Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence | |
| JP5054384B2 (ja) | Ｓａｒｓ関連コロナウイルスの新規系統及びその利用 | |
| Hsu et al. | Artificial mutations and natural variations in the CD46 molecules from human and monkey cells define regions important for measles virus binding | |
| NZ267838A (en) | Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains | |
| EP2959915A1 (en) | A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection | |
| Smith et al. | Structural mutants of dengue virus 2 transmembrane domains exhibit host-range phenotype | |
| Matsuyama et al. | Communication between S1N330 and a region in S2 of murine coronavirus spike protein is important for virus entry into cells expressing CEACAM1b receptor | |
| JP2008511331A (ja) | 修飾されたｈｉｖ−１エンベロープタンパク質 | |
| CA2579507C (en) | Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof | |
| WO2016130786A2 (en) | Flaviviridae proteins and virions and methods of use thereof | |
| CN113736825B (zh) | 一种表达猪非典型瘟病毒融合蛋白的重组果蝇细胞系及其制备方法和应用 | |
| CN113248608B (zh) | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其用途 | |
| EP0997529B1 (en) | Feline immunodeficiency virus strain FIV-141 and uses thereof | |
| Vlaycheva et al. | Neuroblastoma cell-adapted yellow fever virus: mutagenesis of the E protein locus involved in persistent infection and its effects on virus penetration and spread | |
| CN113248607B (zh) | 一种基孔肯雅病毒e2蛋白兔单克隆抗体及其在开发治疗性抗体中的用途 | |
| Tang et al. | Molecular Basis for Adaptation of a Chimeric Dengue Type‐4/Japanese Encephalitis Virus to Vero Cells | |
| Myrmel et al. | Antigenic diversity of Norwalk-like viruses: expression of the capsid protein of a genogroup I virus, distantly related to Norwalk virus | |
| Azarm | The Functional and Antigenic Diversity of the Henipavirus Glycoproteins | |
| Songsivilai et al. | Molecular cloning and expression of hepatitis C virus core protein and production of monoclonal antibodies to the recombinant protein | |
| CN114544950A (zh) | 一种检测寨卡病毒非结构蛋白ns1的elisa试剂盒 | |
| Messera et al. | Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity | |
| MXPA99006629A (en) | Epitopes of the protein pre-m/m of the dengue virus, synthetic peptides | |
| CA2483870A1 (en) | Interacting site for gp41 on gp120 of hiv-1 |